Inactive Instrument

DICE THER Stock

DICE

US23345J1043

Analysts' recommendations: DICE THER

23-06-23	Needham Downgrades DICE Therapeutics to Hold From Buy	MT
23-06-21	SVB Securities Downgrades DICE Therapeutics to Market Perform Rating From Outperform, Adjusts Price Target to $48 From $77	MT
23-06-21	TD Cowen Downgrades DICE Therapeutics to Market Perform From Outperform, Price Target is $48	MT
23-06-21	Guggenheim Downgrades DICE Therapeutics to Neutral From Buy	MT
23-06-21	HC Wainwright Downgrades DICE Therapeutics to Neutral From Buy, Price Target is $48	MT

More recommendations

News in other languages: DICE THER

23-08-10	Les valeurs à suivre aujourd'hui à Wall Street - Jeudi 10 août 2023
23-08-10	Lilly finalise l'acquisition de DICE Therapeutics
23-08-10	EN DIRECTO DESDE LOS MERCADOS: Rheinmetall, Allianz, Novo Nordisk, Walt Disney, Sony, KBC, Siemens, Meta, Ahold...
23-08-10	Bolsa de Madrid: ¡Todo en aumento, mi pobre señorita!
23-08-10	En Direct des Marchés : Alstom, Tapestry, Walt Disney, Sony, KBC, Siemens, Meta, Ahold...

More news

Managers and Directors: DICE THER

Manager	Title	Age	Since
Jonathan Haug CEO	Chief Executive Officer	-	-
Philip Johnson PSD	President	62	2023-08-08
Michael Thompson TRE	Treasurer	-	2023-08-08

Director	Title	Age	Since
Gordon Brooks BRD	Director/Board Member	-	2023-08-08
Michael Thompson BRD	Director/Board Member	-	2023-08-08

More insiders

DICE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing oral therapeutics against well-validated targets in immunology. The Company's platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The Company's therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.

Employees

Sector

More about the company

23-08-11	S&P 500 Edges Down Weekly as US Consumer Prices Moved Modestly Higher in July, Technology, Materials Weigh	MT
23-08-10	Global markets live: Allianz, Generali, Sony, Disney, Alibaba...
23-08-09	Trending : Lilly Gets Price Target Increases, Closes DICE Purchase	DJ
23-08-09	Eli Lilly Completes Acquisition of DICE Therapeutics	MT
23-08-09	Eli Lilly Wraps Up Acquisition of Dice Therapeutics	MT
23-08-09	DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from NASDAQ Composite Index	CI
23-08-09	DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P Pharmaceuticals Select Industry Index	CI
23-08-09	DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P Global BMI Index	CI
23-08-09	DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from S&P TMI Index	CI
23-08-08	Eli Lilly and Company completed the acquisition of DICE Therapeutics, Inc. from a group of shareholders.	CI
23-08-08	DICE Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23-07-28	DICE Therapeutics, Inc.(NasdaqGM:DICE) dropped from NASDAQ Biotechnology Index	CI
23-07-25	Eli Lilly Extends Tender Offer to Acquire DICE Therapeutics to Aug. 9	MT

23-08-09	Lilly Completes Acquisition of DICE Therapeutics	PR
23-07-25	Lilly Announces Extension of Tender Offer to Acquire DICE	PR
23-07-10	DICE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE	BU
23-06-21	DICE THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of DICE Therapeutics, Inc. - DICE	BU
23-06-20	Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology	PR

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/9/23	Jake Simson	Issuer sale	Director	21,250	0.0445%
8/9/23	Mittie Doyle	Issuer sale	Director	42,500	0.0890%
8/9/23	Lisa Bowers	Issuer sale	Director	42,500	0.0890%

DICE THER Stock

Stocks

DICE

US23345J1043

Latest news : DICE THER

Analysts' recommendations: DICE THER

Press Releases: DICE THER

News in other languages: DICE THER

Quotes and Performance

Managers and Directors: DICE THER

Latest insider transactions

Company Profile